TLR4 agonists as immunomodulatory agents
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Monophosphoryl lipid A (MPL®) is a potent vaccine adjuvant derived from Salmonella minnesota that was recently licensed in Europe as a component of an improved vaccine for hepatitis B (Fendrix®). MPL, like lipopolysaccharide from which it is derived, signals via the TLR4/MD-2 complex. We have produced a series of synthetic Toll-like receptor 4 (TLR4) agonists that are based upon the structure of the major hexa-acylated congener contained within MPL. These TLR4 agonists, termed the aminoalkyl glucosaminide phosphates (AGPs), stimulate the production of various cytokines by human peripheral blood mononuclear cells in vitro and up-regulate cell surface markers on monocytes, NK cells and B cells. In addition, AGPs provide non-specific resistance to challenge with viral and bacterial pathogens when administered to the upper airways of mice. Structure—activity relationship studies have shown that the activation of innate immune effectors by AGPs depends primarily on the length of the secondary acyl chains and the nature of the functional group attached to the aglycon component. Moreover, AGPs can act as potent adjuvants for mucosal administration of vaccine antigens, enhancing both antigen-specific antibody and cell-mediated immune responses. Thus, by combining the adjuvant and non-specific resistance induction properties of AGPs it may be possible to generate mucosal vaccines that provide innate protection immediately following administration together with long-term acquired immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fort, M. M., Mozaffarian, A., Stöver, A. G., Correia, J. D. S., Johnson, D. A., Crane, R. T., Ulevitch, R. J., Persing, D. H., Bielefeldt-Ohmann, H., Probst, P., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6416 · Cited by 216
Cited by
New horizons in adjuvants for vaccine development
Reed, S. G., Bertholet, S., Coler, R. N., & Friede, M. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.09.006 · Cited by 618
New horizons in adjuvants for vaccine development
Reed, S. G., Tomai, M., & Gale, M. J. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.08.008 · Cited by 554
Kester, K. E., Cummings, J. F., Ofori‐Anyinam, O., Ockenhouse, C. F., Krzych, U., Moris, P., Schwenk, R., Nielsen, R. A., Debebe, Z., Pinelis, E., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/600120 · Cited by 524
Seubert, A., Monaci, E., Pizza, M., O’Hagan, D. T., & Wack, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.8.5402 · Cited by 430
Vaccine instability in the cold chain: Mechanisms, analysis and formulation strategies
Kumru, O. S., Joshi, S. B., Smith, D. E., Middaugh, C. R., Prusik, T., & Volkin, D. B. (2014) · Biologicals · doi:10.1016/j.biologicals.2014.05.007 · Cited by 404
Metadata
- Authors
- Alderson, M. R., McGowan, P., Baldridge, J. R., & Probst, P.
- Venue
- Journal of Endotoxin Research
- Publisher
- SAGE Publications
- Published
- 2006-10
- Volume
- 12
- Issue
- 5
- Pages
- 313-319
- ISSN
- 0968-0519 (ISSN-L)
- OpenAlex
- W1972230556
- Cited by
- 80
- References
- 1
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TLR4 agonists as immunomodulatory agents. https://app.cochat.ai/papers/10.1177/09680519060120050701
- The paper
- Alderson, M. R., McGowan, P., Baldridge, J. R., & Probst, P. (2006). TLR4 agonists as immunomodulatory agents. Journal of Endotoxin Research. https://doi.org/10.1177/09680519060120050701
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.